Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bispecific CAR T-Cells Yield High Response Rate in Relapsed/Refractory Myeloma

Key clinical point: A chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) and CD38 had a high overall response rate, long response duration, and manageable safety in patients with relapsed or refractory multiple myeloma

Major finding: The overall response rate was about 90% and 9-month progression free survival rate was approximately 79% as of this report. Grade 3 or greater cytokine release syndrome occurred in about 23%, with no cases of neurotoxicity observed.

Study details: Updated results from a phase 1 dose-escalation trial including 22 patients who had received at least two prior lines of therapy.

Disclosures: One study author was affiliated with Cellyan Therapeutics, Wuhan, China. Dr. Hu and coauthors reported that they had no conflicts of interest to declare.


Li C et al. ASH 2019, Abstract 930.